Helsinn Group (Helsinn), a fully integrated, global biopharma company with a diversified pipeline of innovative oncology assets and strong track-record of commercial execution, and BridgeBio Pharma (BridgeBio), a commercial-stage biopharmaceutical company that focuses on genetic
Tags :Matteo Missaglia
BridgeBio Pharma, through its affiliate QED Therapeutics, and Helsinn Group announced a global collaboration and licensing agreement to further develop and commercialize QED Therapeutics’ FGFR1-3 inhibitor, infigratinib, in oncology and all other indications except
On November 21st, inhousecommunity.it celebrated the excellence of the in-house world in Switzerland with its Inhousecommunity Awards Switzerland 2019. The event took place in Lugano, at the cultural centre LAC Lugano Arte e Cultura, in
